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Abstract
Aims This study sought to review the literature for clinical prediction models for the diagnosis of patients with chronic heart
failure in the community and to validate the models in a novel cohort of patients with a suspected diagnosis of chronic heart
failure.
Methods and results MEDLINE and Embase were searched from 1946 to Q4 2017. Studies were eligible if they contained at
least one multivariable model for the diagnosis of chronic heart failure applicable to the primary care setting. The CHARMS
checklist was used to evaluate models. We also validated models, where possible, in a novel cohort of patients with a
suspected diagnosis of heart failure referred to a rapid access diagnostic clinic.
In total, 5310 articles were identiﬁed with nine articles subsequently meeting the eligibility criteria. Three models had under-
gone internal validation, and four had undergone external validation. No clinical impact studies have been completed to date.
Area under the curve (AUC) varied from 0.74 to 0.93 and from 0.60 to 0.65 in the novel cohort for clinical models alone with
AUC up to 0.89 in combination with electrocardiogram and B-type natriuretic peptide (BNP). The AUC for BNP was 0.86 (95%
conﬁdence interval 83.3–88.6%).
Conclusions This review demonstrates that there are a number of clinical prediction rules relevant to the diagnosis of
chronic heart failure in the literature. Clinical impact studies are required to compare the use of clinical prediction rules and
biomarker strategies in this setting.
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Introduction
The diagnosis of chronic heart failure poses major challenges.
Studies have shown that clinical assessment alone is grossly
insufﬁcient in the diagnosis of heart failure with only half of
patients diagnosed having echocardiography evidence of
heart failure.1 However, access to echocardiography is often
limited.2 In the early 2000s, only a third of those with a clin-
ical diagnosis of heart failure had echocardiography or further
referral,3 and this has not changed signiﬁcantly in more re-
cent times.4
Clinical prediction rules are deﬁned as ‘a clinical tool that
quantiﬁes the individual contributions that various
components of the history, physical examination and basic
laboratory results make towards the diagnosis, prognosis,
or likely response to treatment in an individual patient’.5
Such rules have been proposed in a number of areas as a
solution to help guide physicians as to which patients may
need referral. An adapted clinical prediction rule has been
integrated into the National Institute for Health and Care
Excellence guidelines in the UK on the diagnosis of chronic
heart failure.6
The aim of this study was to undertake a systematic re-
view of the literature to identify current clinical prediction
rules used for the diagnosis of chronic heart failure in the
community and to undertake a validation of these rules,
OR IG INAL RESEARCH ART ICLE
© 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
ESC HEART FAILURE
ESC Heart Failure (2019)
Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.12426
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.
where possible, in a novel cohort of patients referred to a
rapid access heart failure diagnostic clinic by their general
practitioner.
Methods
The systematic review was undertaken according to the
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses)7 guidelines and the CHARMS checklist
for systematic reviews of prediction models.8
Search strategy
The review question and design were framed using the
CHARMS checklist for systematic reviews of prediction
models8 (Appendix S1A). A systematic search strategy was
then constructed for use in MEDLINE and Embase (details
on the search syntax can be found in Appendix S1B). In brief,
a search string was developed to identify clinical prediction
rules for the diagnosis of heart failure using terms including
‘heart failure’, ‘cardiomyopathy’ ‘diagnosis’, ‘model’, ‘pre-
dict’, ‘decision’, or ‘score’. We searched for studies on the de-
velopment, validation, and clinical impact of clinical
prediction models for heart failure published between 1946
and Q4 2017. There was no language restriction.
Eligibility criteria
Studies were eligible if they reported multivariable models for
the diagnosis of heart failure in patients in the community.
Inclusion criteria for the systematic review were
(i) patient population: adult human patients,
(ii) multivariable models relating to the diagnosis of heart
failure,
(iii) outcome measure: heart failure, and
(iv) setting of care: hospital outpatient or primary care
(studies of clinical prediction rules conducted in non-
primary care settings were eligible for inclusion if they
were relevant to primary care).
Exclusion criteria were
(i) studies that developed clinical prediction rules for
patients with acute decompensated heart failure only,
(ii) models that were designed to identify patients with
acute heart failure, and
(iii) studies based on single predictors only (as they are
prone to reporting overly optimistic ﬁndings owing to a
number of methodological limitations).
We used broad inclusion criteria to acknowledge variation in
the same-day diagnostic tests that are available across coun-
tries, with the understanding that not all countries will have
access to the same services and that the role of primary
care clinicians also differs internationally. Given the scope
of the systematic review, we assessed all diagnostic predic-
tion models retrieved by our search for their applicability
to primary care. In particular, it must have been possible
for diagnostic predictors or variables to be assessed in the
community or at a general practitioner’s surgery. Variables
such as symptoms and signs, history taking, electrocardio-
gram (ECG), and blood tests are easily obtained, whereas
items such as echocardiography or other advanced imaging
are not.
Critical appraisal
We critically appraised studies using the CHARMS checklist
list (Appendix S1D–F).
Two reviewers (J. G. and D. M.) screened all titles and ab-
stracts and made decisions regarding potential eligibility after
full-text review. In case of doubt, a third reviewer was
consulted.
The reference lists of eligible studies as well as reviews
relating to this subject were hand searched for identiﬁcation
of additional relevant publications. We also requested recog-
nized experts to suggest other articles or sources.
For each included study, the following information was ex-
tracted on the basis of the CHARMS checklist by J. G.: source
of data, participant characteristics, outcomes to be predicted,
candidate predictors, sample size, handling of missing data,
model development, model performance (discrimination
and calibration), and model evaluation (internal or external
validation) and results.
The methodological quality of each article was assessed
using criteria based on a previous systematic review of clinical
prediction rules in primary care based on modiﬁed McGinn
criteria5 in which the criterion concerning ‘100% follow-up’
was changed to ‘adequate follow-up’ and was deﬁned as
≥80% follow-up of study participants.5,9 There were eight
criteria assessing internal and external validity for derivation
studies, and for validation studies, there were ﬁve criteria
(Appendix S1C).
External validation
Rules were validated in a dataset from the new heart failure
diagnostic clinic in the St. Vincent’s Healthcare Group, Dublin.
Only those rules where the variables in the rule were avail-
able in the validation dataset were included. General practi-
tioners referred suspected new-onset cases to the rapid
access clinic, which is part of the heart failure unit. Patients
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whose presentation indicated an acute onset were advised to
go to the emergency department and were not included in
this study. On attending the clinic, all patients underwent a
systematic assessment including medical history and physical
examination by a cardiology registrar and heart failure nurse
specialist. Routine phlebotomy (haematology, renal proﬁle,
and natriuretic peptide) was also performed. Doppler echo-
cardiography was performed in those with a B-type natriuretic
peptide (BNP)> 100 pg/mL; in those with a BNP between 50
and 100 pg/mL already treated with diuretic and/or with a
body mass index (BMI) > 30; and in those with a
BNP < 50 pg/mL with further cardiovascular reason for
echocardiographic assessment. The patient was then
reviewed by a consultant cardiologist, and a decision was
made to conﬁrm or rule out the diagnosis of heart failure
or, in equivocal situations, to send the patient for additional
tests. Patients requiring additional tests were scheduled for
review to conﬁrm or rule out the diagnosis.
Heart failure was diagnosed on the basis of typical symp-
toms, with signs of ﬂuid overload and/or an elevated BNP
(>100 or >50 pg/mL with new diuretic use and/or elevated
BMI), with Doppler echocardiographic evidence of systolic
and/or diastolic dysfunction of the left ventricle or signiﬁcant
valvular disease.
Data analysis
It was possible to validate four rules in our novel cohort on
the basis of the variables available in the cohort and those in
the rules selected. For the four rules to be validated in our
novel cohort, we retrospectively calculated the individual
score or threshold of each included patient on the basis of
models’ parameters. The area under the curve of the re-
ceiver operating characteristics curve, with 95% conﬁdence
intervals (CIs) were used to compare the overall discrimina-
tive ability of rules of the models. We also calculated the
common diagnostic accuracy measures for the rules of the
models, i.e. sensitivity, speciﬁcity, positive predictive values,
and negative predictive values as well as their corresponding
95% CIs.
All calculations including statistical analysis were carried
out using R language version 3.2.3.
Figure 1 PRISMA ﬂow diagram.
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Results
A review of 5310 abstracts led to the identiﬁcation of eight
main models for the diagnosis of heart failure in the com-
munity and one updated model (Table 1).10–18 The search
results are outlined in the PRISMA ﬂow diagram (Figure 1).
One modiﬁcation of a rule was identiﬁed.18 One trial proto-
col for a clinical impact study of a clinical prediction rule
was found.19
Clinical settings for model development
Candidate variables varied widely from ﬁve to 36. Final pre-
dictors in the model varied from ﬁve to 11. Four rules used
symptoms, eight rules used physical examination ﬁndings,
ﬁve rules used ECG ﬁndings, and ﬁve rules used biomarker
data (all relating to natriuretic peptides). The year of publica-
tion of the rules ranged from 2000 to 2016 and became more
common in later years.
Table 2 Candidate and ﬁnal predictors
Fahey
et al.
Rutten
et al.
Yamamoto
et al.
Nielsen
et al.
Kelder
et al.
Roalfe
et al.
Boonman-de
Winter et al.
Oudejan
et al.
Van Riet
et al.
Age ✔ ✔✔ ✔ ✔ ✔✔ ✔✔
Gender ✔✔ ✔ ✔✔ ✔ ✔✔
MI, CABG, or PCI ✔✔ ✔✔ ✔ ✔✔ ✔✔ ✔
Dyspnoea, orthopnoea,
and PND
✔✔ ✔✔ ✔ ✔ ✔✔
Smoking status ✔ ✔ ✔ ✔ ✔
IHD ✔✔ ✔ ✔✔
Medication ✔ ✔ ✔✔ ✔ ✔ ✔
Abnormal ECG ✔✔ ✔✔ ✔✔ ✔✔ ✔ ✔ ✔✔ ✔ ✔✔
BNP/NT-proBNP level ✔✔ ✔ ✔✔ ✔✔ ✔✔ ✔✔ ✔✔
Angina ✔ ✔ ✔ ✔
CCF ✔✔ ✔
BMI/obesity ✔ ✔✔ ✔ ✔ ✔✔ ✔✔
Elevated JVP ✔✔ ✔ ✔✔ ✔ ✔ ✔
Displaced apex beat ✔ ✔✔ ✔✔ ✔✔
Abnormal chest X-ray ✔✔ ✔ ✔
Peripheral oedema ✔ ✔ ✔✔ ✔ ✔✔
Asthma or COPD ✔ ✔
NT-ANP ✔✔
Heart rate ✔✔ ✔ ✔✔ ✔✔
Blood pressure ✔ ✔ ✔ ✔
Wheeze ✔ ✔ ✔✔
heart murmur ✔ ✔✔ ✔✔
Hyperlipidaemia ✔ ✔
Crepitations ✔✔ ✔
TIA/stroke ✔ ✔
Basal rales ✔✔ ✔
Irregularly irregular pulse ✔✔ ✔
Diabetes ✔ ✔
Coronary revascularization ✔
Previous echocardiogram ✔
Cardiovascular co-morbidity ✔ ✔
Nocturia ✔ ✔ ✔ ✔
C-reactive protein ✔ ✔ ✔
Haemoglobin ✔
eGFR ✔
ALT > 2 ULN ✔
GGT > 2 ULN ✔
Abnormal spirometry ✔
Alcohol consumption ✔
Fatigue ✔ ✔
PTCA ✔ ✔
Peripheral vascular disease ✔
Atrial ﬁbrillation ✔ ✔
Loss of appetite ✔✔
Digitalis ✔
Oral anticoagulants ✔
✔, candidate variables; ✔✔, ﬁnal variables; ALT, alanine transaminase; ANP, atrial natriuretic peptide; BNP, B-type naturitic peptide;
CABG, coronary artery bypass graft; CCF, Chronic cardiac failure; COPD, chronic obstructive pulmonary disorder; ECG, electrocardiogram;
eGFR, estimated glomerular ﬁltration rate; GGT, gamma-glutamyl transpeptidase; IHD, ischaemic heart disease; JVP, jugular venous pres-
sure; MI, myocardial infarction; PCI, percutaneous coronary intervention; PND, paroxmal nocturnal dyspnoea; PTCA, percutaneous trans-
luminal coronary angioplasty; TIA, transient ischaemic attack; ULN, upper limit of normal.
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Heart failure subtypes
Six rules addressed heart failure in general [heart failure with
reduced ejection fraction (HF-REF) and heart failure with pre-
served ejection fraction (HF-PEF)], and three rules were for
the prediction of HF-REF only. No rule predicted HF-PEF only.
Three rules were developed for speciﬁc patient populations
(diabetes, geriatric, and chronic obstructive pulmonary
disorder).
Populations
Mean age was reported in eight rules; it varied from 65 to
82 years. One rule reported that only 10% of the patients
were >65 years. The proportion of male patients
ranged from 35.4% to 55.1%. Four rules were derived from
the general practice setting, two from referrals to a
heart failure outpatient clinic, and one from an echocardi-
ography unit. Six rules were derived from prospectively
collected data.
Year of publication
All the studies included in our literature review were pub-
lished between 2000 and 2016.
Stage of development
All clinical prediction articles involved derivation; two rules
were solely derived, two had derivation and internal valida-
tion, and four had derivation and external validation. There
were no clinical impact studies retrieved. However, one clini-
cal prediction rule had a protocol for a clinical impact study
published.19
Clinical setting
The most common setting was general practice (ﬁve studies),
followed by heart failure outpatient clinics (two studies), an
echocardiography clinic (one study), and a geriatric outpa-
tient clinic (one study).
Variables/predictors
There was a wide range of both candidate and ﬁnal variables
used in the studies, which are represented in Table 2.
Bias
Factors affecting bias are outlined in Appendix S1C and in the
CHARMS data table (Appendix S1D–F). A number of studies
involved an unfavourable number of events per candidate
variable, which can lead to overestimation of effect. In a
number of studies, it was also not possible to blind assessors
to the outcome, as this involved a consensus panel to reach
the diagnosis of heart failure. The use of a consensus panel
to establish the diagnosis of heart failure may have resulted
in incorporation bias, by knowing the results of the diagnostic
Table 3 Demographics
Not heart
failure
Heart failure
All Reduced EF Preserved EF
n 448 285 116 169
Agea 75.5 [67.9:81.5] 79.4 [73.0:84.3] 77.7 [70.4:84.2] 80.1 [73.5:84.3]
Malea,b 41.1% 50.5% 61.2% 43.2%
Atrial ﬁbrillationa,b 11.4% 53.7% 44.8% 59.8%
Cancer 7.8% 12.3% 14.7% 10.7%
Cardiovascular diseasea,b 16.7% 34% 47.4% 24.9%
Chronic renal failurea 1.6% 5.6% 8.6% 3.6%
COPD 14.1% 16.1% 19.8% 13.6%
Diabetes 11.6% 16.5% 12.9% 18.9%
Hypertensionb 58.5% 61.8% 49.1% 70.4%
Stroke/TIA 7.6% 8.1% 7.8% 8.3%
Valvular disease 1.8% 3.5% 4.3% 3%
Baseline BMI (kg/m2) 29.6 [26.6:34.0] 29.3 [25.5:34.0] 28.1 [25.2:31.8] 30.0 [26.1:34.6]
Baseline SBPb (mmHg) 141 [129:158] 137 [125:157] 130 [120:151] 143 [129:160]
Baseline DBP (mmHg) 79 [71:87] 78 [68:89] 77 [68:89] 78 [69:90]
Baseline creatininea (mg/dL) 1.10 [0.92:1.32] 1.25 [1.05:1.60] 1.30 [1.09:1.73] 1.19 [1.04:1.47]
Primary aetiology
Hypertensive 43.5% 17.2% 61.5%
Ischaemic 35.8% 59.5% 19.5%
Valvular 9.5% 6.0% 11.8%
Alcohol/drugs 1.8% 4.3% 0%
Idiopathic 4.9% 10.3% 1.2%
Unknown 4.6% 2.6% 5.9%
Bonferroni correction with n = 2 and α = 0.05. Cardiovascular disease includes ischaemic heart disease, peripheral arterial disease and
abdominal aortic aneurysm.
COPD, chronic obstructive pulmonary disorder; DBP, diastolic blood pressure; SBP, systolic blood pressure; TIA, transient ischaemic attack.
aStatistically signiﬁcant for not heart failure vs. heart failure.
bStatistically signiﬁcant for reduced EF vs. preserved EF.
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tests under study. However, there is general consensus that
the resulting overestimation of the performance of some of
the diagnostic items is outweighed by the gain in the accuracy
of the outcome assessment by the panel.
External validation
It was possible to validate four of the rules in our cohort. The
demographics of the validation cohort are presented in
Table 3.
Results of external validation show that clinical prediction
rules perform similarly in the novel cohort as in their original
cohorts (Table 4). However, their performance is similar to
that of BNP alone in this cohort (Figure 2).
Discussion
This study sought to review the literature for clinical predic-
tion rules for the diagnosis of patients with chronic heart fail-
ure in the community and validate them, where possible, in a
novel cohort.
Eight previously developed rules for the diagnosis of
chronic heart failure in the community and one adaptation
of a rule were identiﬁed. Four were externally validated,
and one is undergoing a clinical impact study. In those studies
that estimated the effect of natriuretic peptide on the perfor-
mance of the clinical prediction rule, and in our own valida-
tion study, this biomarker performed as well as, and indeed
better than in some cases, the proposed clinical prediction
rules. It may be that clinical prediction rules based on symp-
toms and signs may not add to the diagnostic process and a
natriuretic peptide-based approach in those patients in
whom the general practitioner considers heart failure as a di-
agnosis may be as useful. Although there are concerns about
overestimation of single-marker models, a biomarker-based
approach should be investigated in comparison with the use
of clinical prediction rules based on symptoms and clinical
signs only for the diagnosis of heart failure in the community
in a clinical impact study. Also the use of multimarker panels
should be researched further. A paper from the REFER study
supports this as natriuretic peptide testing alone performed
as well as the validated clinical prediction rule in determining
which patients presenting with symptoms went on to have a
diagnosis of heart failure. It was also noted that the current
N-terminal proBNP (NT-proBNP) cut-off level of 400 pg/mL
used in the UK is too high and means that one in ﬁve patients
with heart failure may not be appropriately referred for fur-
ther investigation and diagnosis.20
This systematic review of clinical prediction rules in the diag-
nosis of chronic heart failure in the community used an exten-
sive literature search and structured critical appraisal of the
models using the guidance of the CHARMS checklist of the
Cochrane collaboration. The validation cohort in this study is
large compared with that used for the derivation of these Ta
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rules. However, the validation study was conducted in Ireland
in which general practitioners are health care gatekeepers.
Therefore, the results may be less generalizable to health care
settings where primary care does not play such a role. We
were unable to validate four of the rules as some variables
were not available. However, themissing variables such as car-
diothoracic ratio and biomarkers such as adrenomedullin or
atrial natriuretic peptide are not part of current guidelines
and not widely used on a clinical basis. Also, following guide-
lines on validation of clinical prediction models, we wanted
to refrain from simpliﬁcation of these models by excluding
those predictors that were not available and then re-ﬁtting
newmodel on our data, as this would lead to the development
of even more new models. Simply omitting these missing pre-
dictors from the full models without further re-ﬁtting would
lead to structural underestimation of the risk and poor clinical
performance. Therefore, validation of these diagnostic predic-
tion models was not undertaken. Because BNP was used in
some cases to identify those who may not require echocardi-
ography, this may have led to an overestimation of its predic-
tive ability and highlights also the difﬁculty with the use of
single markers in diagnostic prediction. It highlights another
feature of clinical prediction rules in that often features asso-
ciated with the diagnosis are part of the clinical prediction rule,
and therefore, caution should be exercised when using fea-
tures of a clinical prediction rule on their own rather than as
part of the rule. However, the results here are similar to those
of a recently published paper highlighting that NT-proBNP
testing alone performed as well as the MICE (male, infarction,
crepitations, oedema) rule in determining which patients pre-
senting with possible heart failure symptoms went on to have
a diagnosis of heart failure.20
Figure 2 Calibration plots for BNP alone (A), MICE16 rule with BNP (B), and MIJO10 rule with BNP (C). BNP, B-type natriuretic peptide.
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Other systematic reviews on clinical prediction rules
in heart failure have focused on risk prediction, rehospitaliza-
tion, and diagnosis of acute heart failure.21,22 These studies
have also shown a lack of impact analysis, and this has been
noted in other areas of cardiovascular disease also.23 This lack
of clinical application of these rules makes it difﬁcult to deter-
mine the impact that they have on patient care, physician be-
haviour, and health care costs. This review clearly indicates
that many of the studies are similar in design as correspond-
ing models often include similar predictors and include similar
patient populations. Therefore, researchers are often repeat-
ing the same process and mostly introduce implicit knowl-
edge when developing a prediction model from scratch.
Over the past few decades, statistical methods for building
prediction models using established knowledge have substan-
tially improved, and these can be achieved by reﬁning,
updating, extending, and even combining the most promising
existing models for diagnosis of heart failure in the general
population, as was undertaken in the most recent model.18
Ideally, systematic reviews also guide evidence informed
health decision making, in this case leading to recommenda-
tions on which models to advocate or even use in guidelines
for the diagnosis of heart failure. Given the lack of clinical im-
pact studies, we believe it is impossible to recommend which
speciﬁc model or models should be used in which setting or
location. Similarly, the adaptation of models for use in guide-
lines6 without validation may lead to diagnostic inaccuracy
and should be discouraged.
The validity, and thus potential impact, of models for the
diagnosis of heart failure could substantially be improved by
making better use of existing evidence, rather than starting
from scratch to develop yet another model and undertaking
clinical impact studies to determine the utility of these
models. The most suitable and promising models for a partic-
ular targeted population should be identiﬁed and subse-
quently be validated (and if necessary tailored to the
situation at hand), allowing for head-to-head comparisons
such as previously performed for prediction models for the
development of type 2 diabetes.24
Conclusions
The use of clinical prediction rules in chronic heart failure may
help improve access to diagnostics for those most likely to
have signiﬁcant ﬁndings. However, the rules identiﬁed during
this review require further validation and clinical impact stud-
ies before integration into guidelines. In particular, the ap-
proach of using a clinical prediction rule compared with
natriuretic peptide testing or use of a multimarker panel as
a rule-out test in people presenting with symptoms of chronic
heart failure should be evaluated.
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